| scholarly article | Q13442814 |
| P2093 | author name string | Ashwin A Patkar | |
| Chi-Un Pae | |||
| P2860 | cites work | Antipsychotics as antidepressants: what is the mechanism? | Q26995363 |
| Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 | Q28300073 | ||
| The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) | Q29547223 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder | Q31121208 | ||
| Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression | Q33386563 | ||
| Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data | Q33799660 | ||
| Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians | Q33910129 | ||
| The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. | Q34004814 | ||
| Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder | Q34027230 | ||
| The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data | Q34087102 | ||
| Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. | Q34301067 | ||
| A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression | Q34547560 | ||
| Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines | Q34590507 | ||
| Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study | Q34660883 | ||
| Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 | ||
| Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. | Q35142087 | ||
| Treating depression with atypical features | Q36755712 | ||
| Augmentation of antidepressants with atypical antipsychotics: a review of the current literature | Q37062820 | ||
| Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder | Q37692390 | ||
| Quetiapine XR: current status for the treatment of major depressive disorder | Q37716089 | ||
| Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed | Q37777006 | ||
| A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder | Q37795302 | ||
| Second-generation antipsychotics in major depressive disorder: update and clinical perspective | Q37810765 | ||
| Use of risperidone as augmentation treatment for major depressive disorder | Q37824372 | ||
| Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression | Q37917092 | ||
| Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. | Q38383840 | ||
| Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants | Q39304379 | ||
| What predicts attrition in second step medication treatments for depression?: a STAR*D Report. | Q40073042 | ||
| Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis | Q40200644 | ||
| A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder | Q42680831 | ||
| Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies | Q42836142 | ||
| Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial | Q42928152 | ||
| Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies | Q43298201 | ||
| Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder | Q43873455 | ||
| Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression | Q43916260 | ||
| Do atypical features affect outcome in depressed outpatients treated with citalopram? | Q44075173 | ||
| A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes | Q44214684 | ||
| Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression | Q44418347 | ||
| The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study | Q44627462 | ||
| Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. | Q45208467 | ||
| Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study | Q45733394 | ||
| STAR*D: revising conventional wisdom. | Q45931500 | ||
| Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. | Q46018901 | ||
| Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy | Q46315922 | ||
| Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. | Q46825728 | ||
| A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia | Q46826909 | ||
| The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial | Q47239632 | ||
| Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 | ||
| A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. | Q50741608 | ||
| Antidepressant specificity in atypical depression. | Q51190598 | ||
| Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. | Q52076392 | ||
| Number Needed to Treat: What It Is and What It Isn’t, and Why Every Clinician Should Know How to Calculate It | Q56790907 | ||
| A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression | Q57479549 | ||
| Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report | Q57615956 | ||
| Acceptability of second-step treatments to depressed outpatients: a STAR*D report | Q64111530 | ||
| Early nonresponse to fluoxetine as a predictor of poor 8-week outcome | Q71776333 | ||
| Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia | Q73235980 | ||
| Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association | Q73682867 | ||
| Aripiprazole augmentation for treatment of patients with inadequate antidepressants response | Q79366637 | ||
| A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder | Q82274548 | ||
| P304 | page(s) | S39-45 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Clinical issues in use of atypical antipsychotics for depressed patients | |
| P478 | volume | 27 Suppl 1 |
| Q59330199 | A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial |
| Q38148244 | Omega-3 polyunsaturated fatty acids for major depressive disorder |
| Q26797416 | Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice |
| Q52653617 | The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. |
| Q38553417 | Why Systematic Review rather than Narrative Review? |
Search more.